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Oral squamous cell carcinoma (OSCC) is the sixth most common cancer in 
the world. Advancements in management have not improved the overall survival of 
patients during the past 20 years; with 5-year survival rates ranging from 45-50%.
1
 
From the population-based registries in India in the year 2008, covering 1.18 billion 
from different parts of the country, the age adjusted incidence rates are 430.1 per 
100,000 population in males and 518.8 per 100,000 females
2
. The number of new 
cases per year is estimated to be 9.49 lakhs and the number of cancer deaths per year 
around 6.33 lakhs. The risk of getting cancer before age 75 is about 10.4%. Cancers 
of the lip and oral cavity rank the third among all cancers; they account for the 
fourth most common cancer in women and second most common cancer in men.
2
 
The lifetime cumulative risk indicates that an average of one of 10 to 13 people in 
the urban areas are stricken by cancer during their lifetime
3
. Cancers of the oral 
cavity are high in Kerala (south India) and pharyngeal cancers in Mumbai (western 
India). Trend analysis of cancer incidence data for the period 1964–2006 showed 
that the overall rates of cancer are increasing with greater increase among females
4
. 
In the past decade, there has been substantial growth in our comprehension 
of the genetic events underlying the development of OSCC, particularly metastasis. 
Tumors can metastasize through blood vessels (hematogenous spread), lymphatics 
(lymphogenous spread) or by invasion of body cavities (trans-coelomic).  
Hematogenous spread is facilitated by neoangiogenesis at the tumor site. 
Various attempts have been made to use microvascular density as a prognostic 
marker of metastasis in multiple tumor types. The antibodies used in most studies 
are those against vascular endothelium such as factor VIII, antigens CD31, CD34, 
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and more recently CD105 (endoglin). These have also been studied in OSCC. 
However, OSCC metastasizes mainly via lymphatics and its occurrence is a vital 
determinant of cancer progression.  
Lymphangiogenesis which refers to the growth of new lymphatic vessels has 
long been regarded as a precursor pathway to neoplastic metastasisation. 
Interestingly, not much is known about distribution of lymphatics in OSCC and 
visualization of lymphatic vessels has been restricted to imaging techniques 
involving the injection of dyes that are specifically taken up by the lymphatics.
5
 
It has been shown that PA2.26 antigen, a homolog of human podoplanin, is 
upregulated during murine epidermal remodeling and carcinogenesis. Podoplanin 
belongs to the homeobox gene Prox1 family, a master gene controlling the 
development of lymphatic progenitors from embryonic veins.
5 
Induction of PA2.26 
in mouse epidermal cells and tumor cells results in an increase in cell migration and 
malignant transformation.
6
 Podoplanin is also found to promote tumor cell invasion 
by inducing collective cell migration via the down regulation of the activities of 
small Rho family GTPases
7
, reducing cell-cell adhesion and expression of E-
cadherin.
8
 
D2-40 is a recently described selective immunohistochemical marker of 
lymphatic vasculature that belongs to the podoplanin family
6
. It is a novel 
monoclonal antibody against an oncofetal antigen, that is, 40-kDa sialoglycoprotein 
with an O-linked simple mucin-type carbohydrate structure. It is highly expressed on 
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the surface of lymphatic endothelial cells (LECs) but not in blood vascular 
endothelial cells. 
The present study was done to evaluate the expression of D2-40 in formalin 
fixed paraffin embedded tissues of oral squamous cell carcinoma of the buccal 
mucosa with and without history of metastasis and normal buccal mucosa and to 
assess if D2-40 expression correlated with metastasis. 
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Aims and Objectives
 
 To evaluate by immunohistochemistry, the expression of D2 - 40 in formalin 
fixed paraffin embedded tissues of oral squamous cell carcinoma without 
metastasis. 
 To evaluate by immunohistochemistry, the expression of D2 - 40 in formalin 
fixed paraffin embedded tissues of squamous cell carcinoma that has 
metastasised. 
 To evaluate by immunohistochemistry, the expression of D2 - 40 in formalin 
fixed paraffin embedded tissues of clinically normal buccal mucosa. 
 To compare the expression of D2 - 40 between oral squamous cell carcinoma 
with and without metastasis, and normal buccal mucosa. 
 
Hypothesis (Null) 
 There is no change in the expression of D2 - 40 in metastasizing oral 
squamous cell carcinoma, non-metastasizing oral squamous cell carcinoma and 
normal buccal mucosa. 
Hypothesis (Alternate) 
 There is a change in the expression of D2-40 in metastasizing oral squmaous 
cell carcinoma, non-metastasizing oral squamous cell carcinoma and buccal mucosa. 
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Study setting 
The retrospective study was conducted in Department of Oral and 
Maxillofacial Pathology, Ragas Dental College and Hospital, Chennai, using 
archival paraffin embedded tissues. The study was approved by the Institutional 
Review Board. (Annexure 1) Informed consent was obtained from patients for 
samples of normal buccal mucosa for the control group. 
Study sample size 
The study material comprised of 35 formalin fixed, paraffin embedded tissue 
specimens (archival blocks). 
1. 10 histopathologically confirmed buccal mucosal OSCC tissue specimens 
with metastasis.  
2. 15 histopathologically confirmed buccal mucosal OSCC tissue specimens 
that have not metastasized. 
3. 10 normal buccal mucosa tissues specimens. 
 
Study subject 
The study comprised of 3 groups: 
Group 1 – (CASES)         
10 archival blocks of oral squamous cell carcinoma of the buccal mucosa, 
diagnosed histopathologically, that had metastasized to regional lymph nodes. 
15 
 
Group 2- (CASES) 
 15 archival blocks of oral squamous cell carcinoma of buccal mucosa with no 
evidence of metastasis. 
Group 3- (CONTROLS) 
 10 archival blocks of clinically normal buccal mucosa, reporting to the 
outpatient department of oral and maxillofacial surgery for elective removal of 
impacted third molar constituted the control group. 
Methodology 
From the paraffin embedded blocks 5 micron thick sections were cut and 
used for routine hematoxylin and eosin (H & E) staining and immunohistochemical 
(IHC) staining. 
HEMATOXYLIN & EOSIN STAINING 
Reagents 
 Harris’ hematoxylin 
 1% acid alcohol 
 Eosin 
Procedure 
 The slides were dewaxed in xylene and hydrated through increasing grades of 
alcohol (70%, 90% and 100%) to water. 
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 The sections on the slides were flooded with Harry’s hematoxylin for 5 
minutes. 
 The slides were washed in running tap water for 5 minutes. 
 The slides were differentiated in 1% acid alcohol for 30 seconds. 
 The slides were washed in running tap water for 5 minutes. 
 The tissue sections on the slides were then stained in eosin for 30 seconds. 
 The slides were washed in running tap water for 1 minute. 
 The slides were then dehydrated through alcohol, cleared, mounted and viewed 
 under light microscope (LM). 
 
IMMUNOHISTOCHEMISTRY (IHC) 
Armamentarium (Fig. 1) 
 Microtome 
 Autoclave 
 Hot air oven 
 Slide warmer 
 Couplin jars 
 Measuring jar 
 Weighing machine 
 APES coated slides 
 Slide carrier 
 Aluminium foil 
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 Micro-pipettes 
 Toothed forceps 
 Electronic timer 
 Beakers 
 Rectangular steel tray with glass rods 
 Sterile gauze 
 Cover-slips 
 Light microscope 
Reagents used 
1.   Concentrated Hydrochloric acid 
2.   Labolene (Detergent) solution 
3.   APES (3-amino-propyl-tri-ethoxy-silane) 
4.  Acetone 
5.  Citrate buffer 
6.  Phosphated Buffer Saline (PBS) 
7.  3% H2O2 
8.  Deionized and distilled water 
10.  Absolute alcohol 
11.  Xylene 
12.  Protein blocking Serum 
13.  Super Enhancer Reagent 
14.  Chromogen – DAB 
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15.  Delafield’s Hematoxylin – Counter Stain 
16.  Anti Mouse Negative Control Serum 
 
Antibodies used (Fig. 2) 
1.  Primary antibody – D2-40 Anti Mouse - Monoclonal Antibody 
2.  Secondary antibody – Poly Horse Radish Peroxidase 
The primary anti body was from DAKOTM  and the secondary anti body was 
from BiogenexTM. 
Pretreatment of the slides for APES coating 
 The slides were first washed in tap water for few minutes 
 The slides were then soaked in detergent solution for 1 hour 
 After 1 hour, each slide was brushed individually using the detergent 
solution and were transferred to distilled water. 
 The slides were washed in two changes of distilled water and then in 
autoclaved distilled water. 
 The slides were immersed in 1 N HCL (100 ml HCl in 900 ml distilled 
water)     overnight. 
 The following day slides were taken out of acid and washed in two changes 
of autoclaved distilled water. 
 All the slides were then transferred to slide trays, wrapped in aluminium foil 
and baked in hot air oven for 4 hours at 180 degrees centigrade. 
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APES (3 Amino propyl tri ethoxy silane) coating 
Slides first dipped in couplin jar containing acetone for 2 minutes 
Dipped in APES for 5 minutes 
 
                           Dipped in two changes of distilled water for 2 minutes each 
                                                         Slides left to dry 
Preparation of paraffin sections 
After the slides were dry, tissue section of 5 micron thickness were made in a 
rotary manual microtome. The ribbons of tissue section were transferred onto the 
APES coated slide from the tissue float bath such that two tissue bits come on to the 
slide with a gap in between. One of the tissue sections was labelled positive (P) and 
the other negative (N). 
Procedure 
The slides with tissue sections were treated with three changes of xylene to 
remove paraffin wax. They were put in descending grades of alcohol and then 
rehydrated with water. Then the slides were transferred to citrate buffer and 
autoclaved for antigen retrieval at 15 lbs pressure for 30 minutes. Slides were then 
treated with 3% hydrogen peroxide for 10 minutes to quench endogenous peroxidase 
activity of cells that would otherwise result in non – specific staining. Then the 
slides were dipped in 3 changes of deionised water for 5 minutes each. Circles were 
drawn around the tissues, so that the antibodies added later on do not spread and are 
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restricted to the circle. The tissues were incubated in protein blocking serum for 10 
minutes in an enclosed hydrated container. Then the slides were wiped carefully 
without touching the tissue section to remove excess of blocking serum. The 
prediluted primary antibody, monoclonal D2-40 was added to P tissue on the slide 
and then to the N, anti mouse negative control serum was added. The slides were 
incubated for one hour at room temperature in a hydrated container. Then the slides 
were wiped carefully without touching the tissue section to remove excess of 
antibody and washed with three changes of cold PBS for 5 minutes. Then a drop of 
super enhancer reagent was added to enhance the binding of the secondary antibody 
to the primary and was incubated under room temoerature for 20 minutes in a 
hydrated container. Slides were again wiped carefully to remove excess reagent and 
was washed in three rinses of cold PBS. Then a drop of poly horse radish peroxidase 
secondary antibody was added on both the sections and the slides were incubated for 
30 minutes.  Later slides were washed in three changes of cold PBS for 5 minutes in 
each. The slides were wiped carefully without touching the tissue section to remove 
excess PBS. Then a drop of 3-3’ di amino benzedine substrate chromogen was 
added on both sections and incubated for 15 min in room temperature. Slides were 
then washed in deionised water to remove excess chromogen and counter stained 
with Hematoxylin and blued. Then the slides were transferred to ascending 
gradations of alcohol and one change of xylene. The tissue sections were mounted 
with DPX. The slides were then observed under the microscope. Throughout the 
procedure care was taken not to dry the tissues. 
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Positive Control 
A reactive lymph node specimen tissue was fixed, processed, embedded, 
sectioned and stained in the same manner and used as positive control. One positive 
control tissue slide was included for each batch of staining. 
IHC PROCEDURE FLOW CHART 
APES coated slides with 2 paraffin embedded tissues 
Placed in xylene thrice (5 minutes each) 
Placed in 100% isopropanol (5 minutes) 
Placed in 70% isopropanol (5 minutes) 
Washed in distilled water thrice (5 minutes each) 
Kept in citrate buffer pH 6 and autoclaved for antigen retrieval and bench cooled for 
40 mts 
Placed in 3% hydrogen peroxide (10 minutes) 
Washed in deionised water thrice (5 minutes) 
Protein blocking serum added and incubated for 10 min 
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Primary antibody added to the specimen and incubated for one hour 
Washed in PBS thrice (5 minutes each) 
Super enhancer added to the specimen and incubated for 20 min 
Washed in PBS thrice (5 min) 
Secondary antibody added and incubated in an enclosed hydrated container (30 
minutes) 
Washed in PBS thrice (5 minutes each) 
DAB added and incubated in an enclosed hydrated container (15 minutes) 
Washed in deionised water thrice (5 minutes each) 
Stained with Hematoxylin (20 seconds) 
Washed in tap water 
Placed in 70% isopropanol (1 minute) 
Placed in 90% isopropanol (1 minute) 
 
23 
 
Placed in 100% isopropanol (1 minute) 
Placed in xylene (1 dip) 
Slides were mounted using DPX 
Slides were observed under the LM 
Criteria for evaluation of D2-40 staining 
The following parameters were used to evaluate D2-40 staining 
1. Tissue localization of stain – D2-40 staining is localized to endothelium of 
lymphatic vessels 
2. Cellular localization of stain – Cell membrane 
3. Degree of positivity – The number of vessels per mm2 were counted under 10x 
objective through the entire lesion with a grid. The total number of cells counted 
in each tissue section was divided by the number of grids used for each tissue 
section to arrive at the value for the total number of lymphatic vessels per mm
2
. 
(Annexure 2) Each case was graded as absence of stain: no positive lymphatic 
vessels, mild: fewer than five positive lymphatic vessels, moderate: 5 to 10 
positive lymphatic vessels, and severe: more than 10 positive lymphatic vessels.  
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Statistical analysis was done using SPSS 
TM 
software (version 11.5). Krusskal 
Wallis test was done to compare the lymphatic vessels/mm
2
 between the 3 groups 
and Mann Whitney U Test was done to compare the lymphatic vessel density 
between the groups. Pearson’s Chi-square test was done to compare intensity of 
staining between the groups. A p value <0.05 was considered statistically 
significant. 
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Oral Squamous Cell Carcinoma - Epidemiology 
  In developing countries, oral squamous cell carcinoma (OSCC) is the sixth 
most common cancer after lung, prostate, colorectal, stomach and bladder cancer in 
males. While in females it is the tenth most common site of cancer after breast, 
colorectal, lung, stomach, uterus, cervix, ovary, bladder and liver.
9
  
Oropharyngeal carcinoma ranks sixth worldwide for cancer-related 
mortality, with an estimated 5,00,000 new cases diagnosed every year, globally
10
. 
According to estimates from the International Agency for Research on Cancer 
(IARC), there were 12.7 million new cancer cases in 2008 worldwide, of which 5.6 
million occured in economically developed countries and 7.1 million in 
economically developing countries. The corresponding estimates for total cancer 
deaths in 2008 were 7.6 million (about 21,000 cancer deaths a day), 2.8 million in 
economically developed countries and 4.8 million in economically developing 
countries
11
. Nearly a quarter of the newly diagnosed cancers in males from Sri 
Lanka, India, Pakistan and Bangladesh are located in the head and neck region
12
. 
About 6% of oral cancers occur in young people under the age of 45 years
13
.  
The most commonly reported oral cancer sites include the floor of the mouth 
(FOM) and lateral borders of the tongue. The tongue, as a whole, is the most 
common (40- 50%) site for oral SCC in European and American population. Asian 
population usually suffer from cancer of the buccal mucosa due to betel 
quid/tobacco chewing habits
14
.  
27 
 
From the population-based registries in India covering 1.18 billion 
population from different parts of the country, the age adjusted incidence rates were 
430.1 per 100,000 population in males and 518.8 per 100,000 females. The number 
of new cases per year was estimated to be 9.49 lakhs and the number of cancer 
deaths per year was 6.33 lakhs. The risk of getting cancer before age 75 was about 
10.4%. Cancers of the lip and oral cavity rank the third among all cancers, and is the 
fourth most common cancer in women and second most common cancer in men
2
. 
The lifetime cumulative risk indicates that an average of one of 10 to 13 people in 
the urban areas was stricken by cancer during their lifetime
3
. Cancers of the oral 
cavity are high in Kerala (south India) and pharyngeal cancers in Mumbai (western 
India). Trend analysis of cancer incidence data for the period 1964–2006 showed 
that the overall rates of cancer are increasing with greater increase among females
4
. 
Oral Squamous Cell Carcinoma – Risk Factors 
Roughly two thirds of these cases are due to risk factors such as tobacco 
usage and alcohol consumption. Tobacco use is a well-recognized detrimental risk 
factor for the occurrence of OSCC. Approximately 80% of individuals with OSCC 
have used tobacco products. Tobacco users have 5 to 7 times greater risk of 
developing OSCC than non users.  Tobacco use is a major risk factor for oral cancer, 
as well as for cancers in other body sites
15
.
 
 
The function of viruses in the growth of OSCC is well established now. 
Human papilloma virus 16 and 18 have been reported in 22% and 14% of 
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oropharyngeal tumors, respectively, and they increase the risk of OSCC 
development by 3- to 5-fold
16
.  
Substance use increases exposure to carcinogenic tobacco specific 
nitrosamines (TSNA), generation of reactive oxygen species (ROS), and oxidative 
metabolism of pro-carcinogens such as benzo-α-pyrene by cytochrome p450 
resulting  in the generation of reactive carcinogenic intermediates
17
.  
Alcohol consumption is a cofactor in OSCC with tobacco but has also been 
shown to be an independent factor
15
. Its role may involve one or more of the 
following: as a facilitator of passage of carcinogens into cells via the liver by 
enhancing metabolising activity, by activating carcinogenic substances and as a 
local irritant. As with tobacco, there may be variation in the effect on an individual 
due to variation in metabolism. There are allelic variants of alcohol dehydrogenase 
which metabolise alcohol to acetaldehyde, and mitochondrial aldehyde 
dehydrogenase, which metabolises acetaldehyde. Change in activity due to these 
variants, which differ with race, may result in altered acetaldehyde levels which 
inturn are a risk for cancer development. 
Other risk factors for OSCC include dietary deficiencies, 
immunosuppression, poor dental hygiene, sub-mucous fibrosis, gastrointestinal 
reflux and various inherited syndromes. A diet heavy in vegetables and fruit has a 
defensive role in OSCC. The relationship of anemia with oesophageal cancer in 
Patterson Kelly/ Plummer Vinson syndrome is well known, usually in elderly 
females. Immunosuppression, especially post transplant, is related with development 
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of dysplastic lesions. Poor dental hygiene has also been associated with OSCC. 
Literature reveals a role for infection as a co-factor in carcinogenesis e.g. 
inflammation, probably due to Chlamydia
17
.  
Several rare inherited syndromes have been associated with OSCC such as 
Li-Fraumeni syndromes, Bloom syndrome, ataxia telangiectasia and xeroderma 
pigmentosum and dyskeratosis congenita
18
. The main defect is a dysfunction in 
telomere maintenance. The telomeres are repeatedly shortened until they reach a 
critical length, precipitating a genetic crisis in which the surviving cells acquire 
genomic instability, allowing progression to neoplasia. During proliferation, stem 
cells go through telomere shortening, which is counterbalanced by the action of 
telomerase. Short telomeres activate a p53-mediated DNA damage reaction that 
results in decreased tissue regeneration, leading to organ failure. A reduced tissue 
regeneration decreases the probability of accumulating abnormal cells in tissues, 
providing a mechanism for cancer protection. If the stem cells express high levels of 
telomerase (by acquisition of tumorigenic, telomerase-reactivating mutations), stem 
cell mobilization is more efficient than normal. Under these higher mobilization 
conditions, tissue fitness would be maintained for a longer time, increasing lifespan 
and also the probabilities of initiating a tumour
19
.  
Oral Squamous Cell Carcinoma – Clinical Features 
 Common modes of presentation of OSCC are a white patch 
(leukoplakia), a red plaque (erythroplakia), a small exophytic growth which in the 
early stages may show no ulceration or erythema, or a small indolent ulcer. Pain is 
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seldom present in the early stages. Clinical features which should arouse suspicion 
of an early carcinoma are persistent ulceration, induration, and fixation of affected 
tissue to underlying structures. Induration is rubbery hardness caused by invasion of 
the carcinoma resulting in loss of the normal elasticity and compliance of the oral 
mucosa. Fixation is caused by the carcinoma infiltrating through and binding 
together different natural tissue planes. Underlying bone destruction may also be 
detected in the case of carcinomas arising from the alveolar mucosa. Lymph node 
involvement may occur early in oral carcinomas, but enlarged regional nodes do not 
necessarily indicate metastatic spread as they may be due to reactive hyperplasia
20
.  
An advanced or late lesion may present as a broad-based, exophytic mass 
with a rough, nodular, warty, haemorrhagic, or necrotic surface, or as a deeply 
destructive and crater-like ulcer with raised, rolled everted edges. Infiltration of the 
oral musculature may result in functional disturbances, particularly if the tumour 
involves the tongue or floor of mouth. Reduced mobility of the tongue may lead to 
the patients complaining of impaired speech or of difficulty in swallowing. Pain may 
be a feature of an advanced lesion. Bone invasion may be detected on radiographs 
which could be reflected clinically by mobility of teeth and in the mandible, by 
altered sensation over the distribution of the mental nerve, or pathological fracture
20
. 
Oral Squamous Cell Carcinoma – Histopathologic Features 
In well-differentiated tumours, the neoplastic epithelium is squamous in type 
and consists of masses of prickle cells with a limiting layer of basal cells around the 
periphery. Intercellular bridges are readily recognizable. Keratin pearls are often 
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found within the masses of infiltrating cells, each pearl consisting of a central area 
of keratin surrounded by whorls of prickle cells. Nuclear and cellular pleomorphism 
is not prominent and there are relatively few mitotic figures
20
.  
Moderately differentiated tumours show less keratinisation and more nuclear 
and cellular pleomorphism and mitotic activity, but are still readily identified as 
squamous in type. In contrast, in poorly differentiated tumours keratinization is 
usually absent and the cells show prominent nuclear and cellular pleomorphism and 
abundant, often bizarre, mitoses
20
.  
There is variable lymphocytic and plasma cell infiltration in the stroma 
supporting the invasive malignant epithelium, which probably represents a reaction 
by the host's immune system to tumour antigens as well as a response to tumour 
necrosis and ulceration. Most oral squamous cell carcinomas are extremely locally 
destructive. The pattern of infiltration of the adjacent tissues by the neoplastic 
epithelium is variable. In some tumours the appearances suggest a broad front of 
invasion, but in others apparently separate islands of carcinoma or even individual 
malignant cells may be seen well in advance of the main growth. Tumours where the 
invasive front consists of broad groups or sheets of malignant cells are said to have a 
cohesive invasive front, in contrast to those showing small islands, narrow strands, 
or individual cell infiltration which are non-cohesive. Tumours with a cohesive front 
tend to have a better prognosis. Lymphatic permeation, vascular invasion, 
sarcolemmal, and perineural spread may occur. Slender cords of malignant 
epithelium may infiltrate for considerable distances within muscle fibres and along 
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nerve bundles, necessitating a wide surgical excision of such a tumour. Invasion of 
bone occurs as a result of local spread
21
.  
Lymphatic Metastasis:  
Lymphatic metastasis in oral squamous cell carcinoma is a main step during 
tumor progression and its occurrence is a vital determinant of cancer staging, 
treatment, and prognosis. Lymphangiogenesis which refers to the growth of new 
lymphatic vessels has long been regarded as a precursor pathway to neoplastic 
metastasization. The majority of cancer deaths are due to metastatic disease rather 
than primary tumors
22
. Lymph node metastasis signifies tumors that are more 
destructive, forecasts resistance to treatment and denotes the probability of distant 
metastasis. Regional metastasis is related to a 50% decrease in survival, irrespective 
of distant metastasis. The presence of cervical lymph node metastasis is among the 
most important factors for OSCC prognosis and for determination of appropriate 
treatment
22
. Cancer cells release lymphangiogenic growth factors, like Vascular 
Endothelial Growth Factors-C, D and A. These lymphangiogenic growth factors 
stimulate the development of lymphatic vessels by different pathways. VEGF-C is 
the primary lymphangiogenic factor inducing the growth of lymphatic vessels in 
normal and pathologic conditions.
 
The pathway of lymphatic spread was best explained by Zhuang et al with a 
pictorial model by Nathanson (Fig. 3). As tumor progresses, cancer cells give out 
lymphangiogenic cytokines which cause lymphangiogenesis around or within the 
tumor. Cancer cells separate from the primary tumor and invade the extracellular 
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matrix. The chemotactic gradient of chemokines in tissue stimulates the cancer cells 
to move toward lymphatic vessels. After attaching to lymphatic endothelium, they 
cross the endothelial cell barrier and enter into the lymphatic lumen. Then they are 
drained into sentinel lymph nodes within the lymphatic stream. During this process, 
their phenotypes alter. They become resistant to hypoxic environments, secrete 
proteolytic enzymes for invasion, express adhesion molecules, produce 
lymphangiogenic factors to obtain a transport pathway and evade the host defense
23
.  
Lymphatic system seems to have more advantages over blood circulation for 
cancer metastasis. Unlike blood capillaries, lymphatics are much larger and lack a 
continuous basal membrane. Additionally, tumor cells in the lymphatic vessels are 
not prone to serum toxicity, high shear stress, or mechanical deformation. 
Lymphatic spread of OSCC is more vital than in other tumors because they 
preferentially metastasize to around 400 lymph nodes in the head and neck region
23
. 
Several reports have shown the heterogenous distribution of intratumoral and 
peritumoral lymphatic vessels
24
. In the peritumoral regions, large open lymphatic 
vessels were frequently identified. Intratumoral lymphatics, however, were either 
within sheets of tumor cells in carcinomas with a pushing margin or in areas 
containing leukocyte infiltration in carcinomas with an invasive margin. 
Intratumoral lymphatics had numerous tiny ill-defined lumina, often composed of 
two to three endothelial cells. None of the peritumoral lymphatics contain 
proliferating nuclei, while intratumoral lymphatics are proliferative
25
. 
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Cancer cells could release lymphangiogenic growth factors such as VEGF-C, 
D and A. In HNSCC, VEGF-A, C and D positive cells ranged from being present in 
very small numbers to being present throughout almost the entire tumor and VEGF-
C and D expression are frequently up-regulated at the invasive tumor front
25
. These 
lymphangiogenic growth factors were able stimulate the development of lymphatic 
vessels by different pathways. For example, VEGF-A controls endothelial cell 
behaviour by binding with vascular endothelial growth factor receptor-1 (VEGFR-1) 
and VEGFR-2, affecting proliferation, migration, specialization and survival; 
VEGF-C and VEGF-D bind to and activate both VEGFR-3 and VEGFR-2, but not 
VEGFR-1
26
. In addition, VEGF-C and VEGF-D bind to VEGFR-2 with a lower 
affinity than with VEGFR-3
27
.  
Lymphatic endothelial cells might play a positive role in lymphatic metastasis  
Although lymphatic vessels constitute the most important channel of 
lymphatic spread, lymphatic endothelium is an interactive surface for cancer cells 
and the ability of cancer cells to interact with the lymphatic endothelial cell (LEC) is 
a key step in allowing them to invade the lymphatic system. In 2009, Ferreti et al 
observed that tumor cells were washed with the tide of tissue fluid into the 
lymphatic drainage channels. Moreover, interstitial fluid pressure (IFP) in solid 
tumors was significantly elevated compared to normal tissues and increased as 
tumors increased in size, which facilitated tumor cell intravasation and promoted 
metastasis
28
. These results suggest that lymphatic invasion is not an active process, 
but is closely associated with the functional status of LECs. For example, enhanced 
IFP results in increase of interstitial fluid volume (IFV). Thus, the anchoring 
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filaments are stretched and junctions of the endothelial cells opened, allowing cancer 
cells to enter into the lymphatic vessels. Their studies showed that open junction was 
the main junction type in peritumoral lymphatics (about 42%), which had a greatly 
enlarged opening space of 0.3–5 μm. The overlapping junction became the second 
most common junction type in peritumor tissues (38%). The proportion of inlaid 
junctions was 12%, and was 8% for end-end junctions. Therefore, lymphatic 
endothelium itself might have an important influence on the lymphatic metastasis of 
cancer cells
29
.
  
Plasmin, a serine protease and the parent molecule of angiostatin, 
specifically binds to integrin α9β1 through its kringle domains to induce signalling. 
The pro-migratory activity of plasmin requires α9β1 and the catalytic activity of 
plasmin. Protease Activated Receptor-1(PAR-1) is involved in plasmin-induced cell 
migration using PAR agonist peptides and small molecule PAR-1 inhibitors. Thus, 
both α9β1 and PAR-1 are critical for plasmin-induced cell migration
29
.
 
 
 The mannose receptor (MR), lymphatic vessel endothelial hyaluronan 
receptor (LYVE)-1 and common lymphatic endothelial and vascular endothelial 
receptors (CLEVER)-1 direct the traffic of cancer cells into lymphatics
30
.  
Recent studies have shown that LECs in HNSCC have a remarkable degree 
of phenotypic plasticity, characterized by elevated expression of endothelial specific 
adhesion molecules, the transforming growth factor-beta coreceptor Endoglin 
(CD105) and the angiogenesis-associated leptin receptors
31
. These data suggest that 
lymphatic endothelial cells have a major role in metastasis. 
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It is well known that cancer metastasis is not a random process, and 
chemotaxis is an essential component of cancer cell trafficking and metastasis. It is 
assumed that cancer cells actively crawl towards blood and lymphatic vessels 
following the attractant molecule gradients formed by endothelial cells
32
.  
 Evidence suggests that directed movement caused by chemokines is 
required for  tumor metastasis. For example, CCL2 regulates invasion and migration 
of cancer cells by binding to chemokine receptors CCR4
33
; CXCL1, CXCL5, 
CXCL6, CCL2, CCL7, CCL17 and CCL20 were upregulated at mRNA or protein 
level in tongue cancer cell induced LECs
34
, indicating that LECs in tumor could 
secreted chemokines to facilitate the directed migration of tongue cancer cells, 
helping to explain why cancer cells have a predilection for lymphatic metastasis. 
Slit2 is a novel and potent lymphangiogenic factor and contributes to tumor 
lymphatic metastasis. Slit-Robo signaling had been reported to function as 
chemoattractive signal for vascular endothelial cells during angiogenesis. Robo1 is 
expressed in lymphatic endothelial cells to mediate the migration and tube formation 
of these cells upon Slit2 stimulation, which are specifically inhibited by the 
function-blocking antibody R5 to Slit2/Robo1 interaction
35
.  
Lymphangiogenesis as a therapeutic target for OSCC:  
Specific antibodies against lymphangiogenic factors have been developed. 
The humanized VEGF antibody, known as bevacizumab (Avastin™), has been 
approved for treating OSCC. Bevacizumab is being tested in other clinical settings 
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such as adjuvant therapy, maintenance therapy, and in combination with both 
cytotoxic chemotherapy and other targeted agents, such as the epidermal growth 
factor receptor kinase inhibitor, erlotinib. Ramucirumab and IMC-18F1 are 
monoclonal antibodies that target the VEGF receptors VEGFR-2 and VEGFR-1, 
respectively. In addition to anti-angiogenesis therapies, many clinical trials in cancer 
patients are underway or have been completed with inhibitors that have the potential 
to suppress tumor-induced lymphangiogenesis. Inhibition of metastatic spread may 
be achieved by restriction of lymphatic vessel growth by using targeted therapeutic 
strategies against molecules involved in lymphangiogenic signaling, in addition to 
the inhibition of angiogenesis. Recent clinical trials have established that celecoxib, 
a selective COX-2 inhibitor, is of use in enhancing tumor cell apoptosis, thereby 
inhibiting the growth and angiogenesis of tumors by inhibiting COX-2, PGE2 
synthesis, and VEGF expression in tumors.
36 
Lymphatic Markers:  
Progress in understanding lymphangiogenesis has been hampered by the 
very similar characteristics of blood and lymphatic vessels in tissue section and was 
confounded by the lack of lymphatic-specific markers. Consequently, visualization 
of lymphatic vessels in the past was restricted to imaging techniques involving the 
injection of dyes that are specifically taken up by the lymphatics. Vital dyes, such as 
Evans blue and trypan blue which are readily taken up by lymphatic but not blood 
vessels, are less toxic than the materials that were previously used
37
. Until recently, 
immunohistochemical identification of lymphatic vessels was achieved, somewhat 
unreliably, by comparing staining of pan-endothelial markers with markers of the 
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basal lamina. The pan-endothelial marker PECAM-1/CD31, which is expressed on 
both blood and lymphatic vessels, has been used in combination with the basement 
membrane markers namely, laminin and collagen type IV
38
. Vessels that reacted 
with PECAM-1 antibodies but lacked basement membrane staining and red blood 
cells in their lumens were deemed lymphatic. Vascular endothelial growth factor 
receptor-3 (VEGFR-3) is predominantly expressed on lymphatic endothelium in 
normal adult tissues; it is also up-regulated on blood vessel endothelium in tumors
39 
and in wound healing
40
.  
The lymphatic receptor for hyaluronan, LYVE-1, has been reported to be a 
specific marker of lymphatic vessels and is thought to function in transporting 
hyaluronan from the tissue to the lymph
41
. Antibodies to LYVE-1 have been used to 
localize the receptor to lymphatic endothelium in normal and tumor tissue
42
. 
Podoplanin and desmoplakin have been reported to be markers for lymphatic 
endothelium, of which D2-40 is a specific marker belonging to the podoplanin 
family. The markers for discrimination of lymphatics and blood vessels have been 
enlisted in (Fig. 4). 
D2-40 – Structure                                
D2-40 of the podoplanin family is a novel monoclonal antibody against an 
oncofetal antigen, the M2A antigen, consisting of a 40-kDa sialoglycoprotein with 
an O-linked simple mucin-type carbohydrate structure, highly expressed on the 
surface of lymphatic endothelial cells (LECs) but not of blood vascular endothelial 
cells. Although studies in podoplanin knockout mice demonstrated that this protein 
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is essential for the correct formation and function of the lymphatic vascular system 
and it is one of the most commonly exploited markers for lymphatic vessels, the 
exact molecular function of podoplanin in the lymphatic endothelium has remained 
unclear. Moreover, the expression of podoplanin is up-regulated in several human 
cancers and might be associated with their malignant progression.
21
 
Studies that have shown D2-40 Positivity 
 Observed in all layers of oral sulcular and junctional epithelia associated 
with severe inflammatory reaction in the connective tissue.
43
  
 Observed at the periphery of sebaceous glands and in skin lymphatic 
endothelium of all specimens, demonstrating that podoplanin is expressed in 
sebaceous glands of normal skin.
44
  
 Expression of podoplanin in ameloblastomas is considered to be associated 
with neoplastic odontogenic tissues; this molecule might play a role in the 
collective cell migration of tumor nests in ameloblastomas.
45
  
 Expressed in osteocytes or osteoblasts.46  
 Detected in the cell membrane and cytoplasm of most of the basal and 
suprabasal layer, areas of budding basal cell proliferation, epithelial nests 
and peripheral cells of daughter cysts in the stromal connective tissue in 
Keratinising Cystic Odontogenic Tumors.
47
 
 Mice lacking podoplanin, have malformed lymphatic vasculature with 
lymphedema at birth.
48 
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 Increase in podoplanin-expressing intestinal lymphatic vessels in 
inflammatory bowel disease.
49
 
 Reliably identifies the myoepithelial cells of breast in a variety of lesions.50 
 D2-40 expression could be identified around outer root sheath of hair 
follicles.
51,52
 
 D2-40 antibody is a useful cell surface marker for isolation of human neural 
stem/progenitor cells and/or neuronal lineage cells in techniques such as 
fluorescence-activated cell sorting.
53
  
 Positive for astrocytes in the brain.54  
 Positive for perineurium of peripheral nerves.55  
 
Podoplanin expression was analysed in 35 patients with HNSCC including 
16 oral tumors and 19 hypopharyngeal tumors by immunohistochemical analysis 
and the association between the podoplanin expression status and patients' clinical 
and pathologic characteristics was evaluated. An independent set of 60 patients with 
oral tongue cancer was then analyzed for associations between the podoplanin 
expression status and patients' clinical and pathologic characteristics, including 
survivals.  Podoplanin was not expressed in normal oral epithelial cells but was 
detected in some hyperplastic and dysplastic lesions. High podoplanin expression 
was found in 57% of the tumors and was more frequent in tumors with lymph node 
metastasis, particularly in tumors of the oral cavity. In the second set of 60 oral 
tongue cancers, 60% expressed high levels of podoplanin. Hence they concluded 
that Podoplanin is involved in oral tumorigenesis and may serve as a predictor for 
lymph node metastasis and poor clinical outcome
56
.  
41 
 
The value of peritumoral and intratumoral lymphatic vessel density (LVD) 
was assessed as a prognostic marker for HNSCC. Thirty-one cases of HNSCC were 
stained for D2-40 and CD31. LVD and blood vessel density (BVD) were assessed 
by counting positive reactions in 10 hotspot areas at ×200 magnification. D2-40 was 
specific for lymphatic vessels and did not stain blood vascular endothelial cells. 
LECs showed more tortuous and disorganized structure in intratumoral lymphatic 
vessels than in peritumoral ones. No statistical differences were observed between 
peritumoral-LVD and intratumoral-LVD or between peritumoral-BVD and 
intratumoral-BVD. Tumor D2-40 staining was positively associated with lymphatic 
vessel invasion. LVD is a powerful marker for HNSCC prognosis. We found 
significant differences in peritumoral and intratumoral D2-40 immunoreactivity, 
which could have important implications in future therapeutic strategies and 
outcome evaluation
57
.  
Endogenous or recombinant human podoplanin was purified, and total 
glycosylation profiles were surveyed by lectin microarray. Analyses of 
glycopeptides produced by Edman degradation and mass spectrometry revealed that 
the disialyl-corel (NeuAca2-3Galbl-3(NeuAca2- 6)GalNAcal-O-Thr) structure was 
primarily attached to a glycosylation site at residue Thr52. Sialic acid-deficient 
podoplanin recovered its activity after additional sialylation. These results indicated 
that the sialylated Corel at Thr52 is critical for podoplanin-induced platelet 
aggregation
58
.  
Immunohistochemistry of antipodoplanin and D2-40 was performed in 55 
mesotheliomas (24 epithelioid, 18 sarcomatoid, and 13 biphasic), 80 pulmonary 
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adenocarcinomas, 8 synovial sarcomas, and 16 sarcomatoid carcinomas. Expression 
of calretinin, vimentin, MOC31, and TTF-1 was also examined in all 
adenocarcinomas, sarcomatoid carcinomas, 7 synovial sarcomas, and 21 of the 
mesotheliomas. Calretinin staining performed previously on an additional 31 
mesotheliomas was reviewed. Using membranous or cytoplasmic staining as 
indicative of positivity, they found that antipodoplanin and D2-40 each stained 84% 
of mesotheliomas, including 72% of sarcomatoid mesotheliomas. With 
antipodoplanin antibody, no staining was seen in the pulmonary adenocarcinomas or 
the synovial sarcomas and weak cytoplasmic staining was seen in only 1 
sarcomatoid carcinoma. D2-40 showed similar results, staining 3% of pulmonary 
adenocarcinomas, 13% of synovial sarcomas, and 8% of sarcomatoid carcinomas. 
Overall sensitivities and specificities were 84% and 99% for antipodoplanin, and 
86% and 96% for D2-40. These findings suggested that cytoplasmic podoplanin 
expression may be useful in the diagnosis of sarcomatoid mesothelioma, although it 
should be used with caution on biopsy material
59
.  
Podoplanin expression was determined in 150 Oral Leukoplakia (OPL) 
patients with long-term follow-up using immunohistochemistry. Association 
between the protein expression patterns and clinicopathologic parameters including 
oral cancer development during the follow-up were analyzed. 37% of the 150 OPL 
patients exhibited podoplanin expression in the basal and suprabasal layers and were 
classified as podoplanin positive. Podoplanin positivity was more frequent in older 
patients, females, and dysplastic lesions. Patients with OPL that was podoplanin 
positive had significantly higher incidence of oral cancer than did those whose OPL 
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was podoplanin negative. In the multivariate analysis using histology and 
podoplanin as cofactors, podoplanin was the only independent factor for oral cancer 
development. Together with histology, podoplanin may serve as a powerful 
biomarker to predict the risk for oral cancer development in patients with OPL
60
.  
Immunoreactivity for podoplanin was studied in the cell membrane and 
cytoplasm of basal cells of oral gingival epithelium when severe inflammatory cell 
infiltration was present in the connective tissue just under the epithelium. When 
inflammatory changes were weak or absent, little or no reactivity for podoplanin in 
the basal cells was observed. Positive reactivity for podoplanin was also detected in 
basal cell extensions. Surprisingly, strong immunoreactivity for podoplanin was 
observed in all layers of oral sulcular and junctional epithelia associated with severe 
inflammatory reaction in the connective tissue. These findings suggested that 
increased expression of podoplanin in gingival epithelium is related to the 
progression of chronic periodontitis
43
.  
Nine human tooth germ biopsies were examined and seven healthy 
permanent teeth extracted for orthodontic reasons. Anti-podoplanin (D2-40) 
reactivity was investigated immunohistochemically. Five well-defined cystic 
odontogenic lesions (10 radicular cysts, 10 follicular cysts, three keratocystic 
odontogenic tumours, five ameloblastomas, and two adenomatoid odontogenic 
tumours) were analysed simultaneously. Podoplanin expression was detected in the 
majority of epithelial and ectomesenchymal cells of human tooth germ tissues, 
odontoblasts and superficial dental pulp fibroblasts of permanent teeth. Cystic 
odontogenic lesions revealed positive reactions predominantly at the invasion front 
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edge within basal epithelial layers. They concluded that podoplanin appears to be 
involved in the orthologic and pathologic processes of the formation of elongated 
cell extensions and odontoblastic fibers, in the epithelial–mesenchymal transition 
and local invasion during tooth germ development as well as in both reactive and 
neoplastic odontogenic cystic lesions
61
.  
Podoplanin and ABCG2 expressions were determined in samples from 110 
patients with untransformed oral lichen planus (OLP) and 9 patients with malignant 
transformed OLP (mean follow-up of 5.1 years). They compared podoplanin 
expression, ABCG2 expression, and clinicopathologic parameters between the two 
groups. The expressions of podoplanin and ABCG2 in OLP were significantly 
associated with malignant transformation risk. Their data suggested that podoplanin 
and ABCG2 may be used as biomarkers for risk assessment of oral malignant 
transformation in patients with OLP
62
. 
Immunohistochemical expression of D2-40 was analysed in the normal 
human thymus and thymoma. In both fetal and postnatal normal thymus, they found 
a strong expression of D2-40 in the subcapsular and cortico-medullary epithelial 
cells, and lack of expression in the thymus of involution. These findings support a 
role for podoplanin in the proliferation of some subtypes of epithelial cells of the 
normal thymus stroma. In thymoma, the expression of D2-40 was detected in 
neoplastic cells in 18 from 26 cases (69.23%). No correlation was found between 
D2-40 expression and histological types of thymoma, but strong correlation was 
noticed with tumor stage. Based on these results, it is suggested that D2-40 
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expression is a good predictor of invasion and can be considered as a potential target 
for therapy in selected cases
63
.  
The density of lymphatic vessels was analysed in 52 cases of human tongue 
squamous cell carcinoma (TSCC) and normal portions. TSCC specimens were 
immunostained with antibodies against lymphatic vessel endothelial hyaluronan 
receptor 1 (LYVE-1) and podoplanin monoclonal antibody (D2-40). The 
significance of the LYVE-1-positive vessel density (LVD) was calculated in 6 
topographic areas and investigated on the basis of specific clinical and 
histopathological parameters. LYVE-1 positivity was more evident in the muscular 
area than the submucosal area, while small D2-40-positive lymphatic vessels were 
not demonstrable in muscular endomysium. The LVD in peri-tumoral submucosal 
and peri-tumoral muscular areas was lower than in normal counterparts. LVD was 
higher in the tumor invasion front as compared to tumor-associated stroma. Low 
LVD in invasion front and peri-tumoral submucosal area was significantly related to 
regional lymph node metastasis. The decrease of LYVE-1-positive lymphatic 
vessels in the invasion front and peri-tumoral submucosal area would seem to 
predict cervical lymph node metastasis in TSCC
64
.  
Epidermal growth factor receptor (EGFR) expression was determined in 40 
retrospective OSCC specimens and its correlation with proliferating cell nuclear 
antigen (PCNA), antiapoptotic antibody (P53), vascular endothelial growth factor 
(VEGF), and D2-40 monoclonal antibodies (Mab), in relation to the 
clinicopathological parameters. Data revealed positive EGFR immunoreactivity in 
87.5% cases. There was a statistically significant correlation regarding EGFR extent 
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score with respect to intratumoral lymphatic vessel density (ILVD) as well as EGFR 
intensity score with respect to ILVD and peritumoral lymphatic vessel density 
(PLVD). EGFR expression was not correlated with the clinicopathological 
parameters. CEGFR is expressed by most of the cases. EGFR correlation with D2- 
40 positive lymphatic vessels suggests a higher tendency of OSCC for lymphatic 
dissemination. Lack of correlation among the studied markers suggests their 
independent effect on tumor behavior
65
. 
Small interfering RNA (siRNA) depletion of podoplanin expression in 
HMVEC-LLy inhibits VEGF-induced microtubule-organizing center (MTOC) and 
Golgi polarization and causes a dramatic reduction in directional migration 
compared with control siRNA-transfected cells. Their results indicate that polarized 
migration of lymphatic endothelial cells in response to VEGF is mediated via a 
pathway of podoplanin regulation of small GTPase activities, in particular Cdc42
66
.  
A positive correlation between the D2-40 staining intensity and 
histopathological stage in Kaposi Sarcoma (KS) cases was reported. D2-40 
immunoreactivity was detected at all histopathological stages of KS and widespread 
D2-40 protein expression indicated evidence of a lymphatic origin or the 
differentiation of neoplastic cells in KS, and D2-40 expression increased with tumor 
progression
67
. 
A total of 298 foci of squamous cell carcinoma (SCC), carcinoma in situ 
(CIS), epithelial dysplasia, and hyperplastic and/or normal epithelial lesions was 
studied by immunohistochemistry using D2-40. There was no positivity for 
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podoplanin in normal or hyperplastic epithelia, while all of the CIS and SCC foci 
stained positive. Approximately one third of the mild dysplasia foci (10 of 36 foci, 
28%) and 80% of moderate dysplasia foci (78/98) showed grade 1 positive reactions 
(positive only in the 1st layer). Grade 2 reactions (up to 4th layer) were seen in 4 of 
98 moderate dysplasia foci (4%), 29 of 74 CIS foci (39%), and 3 of 30 SCC foci 
(10%). Grade 3 reactions (to more than 5th layer) were found in 35 (47%) CIS foci 
and 26 (87%) SCC foci. The relationship between the present histological 
categorization and podoplanin grade was statistically significant. D2-40 expression 
was considered to be related to the severity of oral precancerous lesions
68
. 
D2-40 reactivity was studied in resected specimens of superficial squamous 
cell carcinoma of the esophagus (SSCCE) to accurately assess lymphatic tumor 
emboli (LY) and to analyze correlations between LY and lymph node metastasis 
(N). 75 patients with SSCCE who underwent surgical resection of their tumors were 
studied. Resected specimens were sliced into continuous sections at 5 mm intervals. 
Intramucosal cancers are classified into three groups (m1, m2, m3), and submucosal 
cancers are also divided into three groups (sm1, sm2, sm3). The numbers of LY 
present in lymphatic ducts on D2-40 immunostaining, venous tumor emboli (V) on 
CD34 immunostaining, and lymphatic tumor emboli (ly) and V on hematoxylin-
eosin staining (HE) and elastica van Gieson staining (EVG) were counted for each 
case. The presence of lymphatic tumor emboli was graded according to the total 
number of LY per case as follows: 0, LY0; 1 to 2, LY1; 3 to 9, LY2; and 10 or 
more, LY3. All m1 and m2 cases were LY- and N- Lymphatic tumor emboli were 
present in 54% of m3 cases, 70% of sm1 cases, 54% of sm2 cases, and 75% of sm3 
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cases. Determination of N was positive in 18% of m3 cases, 47% of sm1 cases, 36% 
of sm2 cases, and 62% of sm3 cases. Evaluation of lymphatic invasion on the basis 
of LY was more accurate for the prediction of N than conventional techniques and 
LY grade strongly correlates with N. In patients with SSCCE, mucosal cancers (m1, 
m2, and m3) and submucosal cancers with a depth of invasion of ≤200 μm from the 
lower margin of the muscularis mucosae on endoscopic mucosal resection have a 
low risk of N if the number of LY is 0. Endoscopic mucosal resection alone can 
provide good treatment outcomes in such patients
69
. 
Sections from 80 paraffin-embedded archival specimens of invasive breast 
cancer stained were studied for podoplanin, D2-40, or CD31 expression. 
Immunohistochemical staining results were correlated with clinicopathological 
features, such as tumor size, status of lymph node metastases, estrogen receptor 
status, progesterone receptor status, human epidermal growth factor receptor-2 
expression, and recurrence. Patients with ductal carcinoma in situ and stage IV 
breast cancer were excluded. A significant correlation was found between D2-40 
LVI positivity and lymph node metastasis (p=0.022). They found a significant 
correlation between D2-40 LVI positivity and recurrence of breast cancer (p=0.014). 
However, no significant correlation was found between BVI and recurrence. A 
poorer disease free survival was shown for D2-40 positive LVI (p=0.003). In a 
multivariate analysis, the presence of D2-40 LVI positivity revealed a significant 
association with decreased disease-free survival
70
. 
On evaluating whether the use of lymphatic endothelial marker D2-40 and 
panvascular marker CD34 increases LVI positivity relative to routine histology 
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alone and then evaluated the prognostic relevance of LVI detected using these 
markers in terms of disease-free (DFS) and overall survival (OS). A total of 246 
primary melanomas were assessed for LVI using D2-40, CD34, and routine 
histology. Associations between LVI positivity and clinicopathologic variables, 
DFS, and OS were compared using univariate and multivariate analyses. The use of 
endothelial markers increased the rate of LVI positivity (18% using D2-40 and/or 
CD34 vs. 3% by routine histology, P<0.0001). On univariate analysis, IHC-detected 
LVI was significantly associated with more adverse clinicopathologic variables 
(thickness, ulceration, mitoses, and nodular subtype) compared with LVI detected 
by routine histology (thickness and ulceration only). In a multivariate model 
controlling for stage, LVI detected using IHC markers remained a significant marker 
of both reduced DFS [hazard ratio (HR), 2.01; 95% confidence interval (CI): 1.27-
3.18; P=0.003] and OS (HR, 2.08; 95% CI: 1.25-3.46; P=0.005). Results showed 
that D2-40 and CD34 increase the detection of LVI in primary melanoma and that 
cases missed by routine histology have prognostic relevance
71
. 
Lymphatic microvascular density (LMVD) was quantified in thin (≤1.0 mm) 
superficial spreading melanomas comparing regressive and nonregressive 
melanomas, regressive and nonregressive areas from the same tumor, and early and 
late histological stages of regression in the same tumor. In addition, they tried to 
correlate lymphangiogenesis and tumor growth phase. They conducted histological 
examinations and immunohistochemical analyses using monoclonal antibody D2-40 
with subsequent quantification by image analysis of 37 melanomas, 16 regressive 
and 21 nonregressive (controls). Higher LMVD was found in the late stage of 
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regression compared with nonregressive area (internal control) of regressive 
melanomas. The late stage of spontaneous regression in thin melanomas may be 
related to worse prognosis as it showed higher LMVD, and evidence shows that this 
is related with increased risk of metastatic spread
72
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The study population (n=35) consisted of 68.6% men and 31.4% women. In 
Group 1, metastatic OSCC group (n=10), 80% were men and 20% were women 
Group 2, the non metastatic OSCC group (n=15), 80% were men and 20% were 
women; and in Group 3, the control group (n=10), 60% were men and 40% were 
women (Graph 1). 
The patients’ age ranged from 21 to 35 years (mean 27.6 ± 4.35) in control 
group, from 33 to 76 years non metastatic OSCC group and from 41 to 80 years 
(mean 62.5 ±12.93) in metastatic OSCC. 
In the non metastatic OSCC group (n=15), 86.6% (n=13) were well 
differentiated OSCC, 6.7% (n=1) was moderately differentiated OSCC and 6.7% 
(n=1) was poorly differentiated OSCC. In metastatic OSCC group (n=10), 40% 
(n=4) were well differentiated OSCC, 50% (n=5) were moderately differentiated 
OSCC and 10% (n=1) were poorly differentiated OSCC (Graph 2). 
 D2-40 staining was observed in 80% (n=8) of the cases in the control group, 
100% (n=15, n=10) cases in non metastatic OSCC and metastatic OSCC group 
respectively (Graph 3).  
A lymph node tissue section was used as a positive control to confirm D2-40 
positivity to lymphatics (Fig. 5A). D2-40 expression was observed selectively in the 
endothelium of the lymphatic vessels and was not detectable in the endothelial cells 
of the blood vessels (Fig. 5B). D2-40 positive lymphatic vessels were scarce in the 
sections of normal buccal mucosa (Fig.6) when compared to non metastatic OSCC 
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(Fig. 7 A and B) and metastatic OSCC (Fig. 8 A and B). In the basal layer of the 
epithelium, in some of the hyperplastic and dysplastic epithelial areas, areas with 
juxta epithelial inflammatory cell infiltrate and areas flanking the tumor cells in the 
connective tissue, D2-40 was highly expressed (Fig. 9 A and B). D2-40 expression 
of the tumor cells was noticed either as focal expression at the proliferating 
periphery of the well differentiated tumor cell nests with no expression in the central 
areas (Fig. 10 A and B) or diffusely in the central areas of less differentiated tumors 
(Fig. 11 A and B).  
Comparison of number of lymphatic vessels/mm
2
 between the control group 
and the non metastatic OSCC group (Table 1): 
There was a statistically significant difference between the control and non 
metastatic OSCC groups with respect to the number of lymphatic vessels per mm
2
 (p 
= 0.001), with the non metastatic group showing more lymphatics as compared to 
the control group. The mean number of lymphatic vessels per mm
2
 in the control 
group (Range: 0-2.29) was 0.55 (S.D = 0.80) and in the non metastatic OSCC group 
(Range: 0.67-3.6) was 2.15 (S.D = 1.002). 
Comparison of number of lymphatic vessels/mm
2
 between the control group 
and the metastatic OSCC group (Table 2): 
This comparison revealed a statistical significance in the difference in the 
number of lymphatic vessels per mm
2
 between the control group and the metastatic 
group (p = 0.000), with an increase in number of lymphatics in the metastatic OSCC 
group when compared to control group with a mean 0.55 (S.D=0.798) lymphatics 
54 
 
per mm
2
 (Range: 0-2.29) for control group and 5.75 (S.D=2.610) for metastatic 
OSCC group (Range: 0.81-8.9). 
Comparison of number of lymphatic vessels/mm
2
 between the non metastatic 
OSCC group and the metastatic OSCC group (Table 3): 
Between the non metastatic OSCC group and the metastatic OSCC group, 
there was a statistically significant difference in the number of lymphatic vessels per 
square millimetre (p = 0.001) with the metastatic OSCC group showing more 
lymphatic vessels when compared to the non metastatic OSCC group with a mean of 
2.15 (S.D=1.002) lymphatic vessels per mm
2
 for non metastatic OSCC group 
(Range: 0.67-3.6) and 5.75 (S.D=2.610) for metastatic OSCC group (Range: 0.81-
8.9). 
Comparison of number of lymphatic vessels/mm
2 
between the three study 
groups (Table 4):  
On comparison of the number of lymphatic vessels per square millimetre 
among the different study groups, it was observed that there was a statistically 
significant difference between the different groups (p = 0.000) with metastatic 
OSCC group showing more lymphatic vessels when compared to non metastatic 
OSCC group, which in turn showed more number of lymphatic vessels when 
compared to the control group, with a mean of 0.55 (S.D=0.798) for control group, 
2.15 (S.D=1.002) for non metastatic OSCC group and 5.75 (S.D=2.610) for 
metastatic OSCC group. 
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Comparison of intensity of lymphatic vessels between the three groups (Table 5, 
Graph 4): 
On evaluating the intensity of staining in the study groups, 80% (n=8) cases 
in control group showed mild intensity and 20% (n=2) cases showed absence of 
stain. In non metastatic OSCC group, 100% (n=15) cases showed mild intensity and 
in metastatic OSCC group, 30% (n=3) cases showed mild intensity and 70% (n=7) 
cases showed moderate intensity, and this difference was statistically significant 
(p=0.000) 
Comparison of intensity of lymphatic vessels between different histopathologic 
grades of OSCC (Table 6, Graph 5): 
 Among the well differentiated OSCC cases (n=17), 82% (n=14) showed mild 
intensity and 18% (n=3) showed moderate intensity. In the moderately differentiated 
OSCC (n=6), 50% (n=3) showed mild intensity and 50% (n=3) showed moderate 
intensity. 50% (n=1) cases showed mild intensity and 50% (n=1) cases showed 
moderate intensity in the poorly differentiated OSCC group (n=2); and this 
difference was not statistically significant (p=0.075) 
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Graph 1 
Distribution of gender among study groups 
 
Graph 2 
Pathologic grading of non metastatic and metastatic OSCC groups 
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Graph 3 
D2-40 Positivity among study groups 
 
Graph 4 
Distribution of staining intensity among the study groups 
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Graph 5 
Distribution of staining intensity among different pathologic grades of OSCC 
 
Table 1 
Comparison of lymphatic vessels/mm
2 
between Group 2 and Group 3 
Group N Mean S.D Min 
Value 
Max 
Value 
Mean 
Rank 
p Value* 
Group 2 15 2.15 1.002 0.67 3.6 17.07 
0.001 
Group 3 10 0.55 0.798 0 2.29 
6.90 
Total 25 1.51 1.208 0 3.6 
 
* p value obtained from Mann Whitney test 
   p value less than 0.05 was considered statistically significant 
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Table 2 
Comparison of lymphatic vessels/mm
2 
between Group 1 and Group 3 
Group N Mean S.D 
Min 
Value 
Max 
Value 
Mean 
Rank 
p Value* 
Group 1 10 5.75 2.610 0.81 8.9 15.30 
0.000 
Group 3 10 0.55 0.798 0 2.29 5.70 
Total 20 3.15 3.262 0 8.9  
* p value obtained from Mann Whitney test  
   p value less than 0.05 was considered statistically significant                                                          
 
Table 3 
Comparison of lymphatic vessels/mm
2 
between Group 1 and Group 2 
Group N Mean S.D 
Min 
Value 
Max 
Value 
Mean 
Rank 
p 
Value* 
Group 1 10 5.751 2.610 0.814 8.9 18.90 
0.001 Group 2 15 2.147 1.002 0.666 3.6 9.07 
Total 25 3.588 2.527 0.666 8.9  
* p value obtained from Mann Whitney test 
   p value less than 0.05 was considered statistically significant 
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Table 4 
Comparison of lymphatic vessels/mm
2 
between the study groups 
Group N Mean S.D 
Min 
Value 
Max 
Value 
Mean 
Rank 
p Value* 
Group 1 10 5.75 2.610 0.81 8.9 28.70 
0.000 Group 2 15 2.15 1.002 0.67 3.6 18.13 
Group 3 10 0.55 0.798 0 2.29 7.10 
Total 35 2.72 2.572 0 8.9  
* p value obtained from Kruskal Wallis Test 
   p value less than 0.05 was considered statistically significant 
 
Table 5 
Comparison of intensity of lymphatic vessels between the three groups 
Intensity 
Group 1 Group 2 Group 3 p Value * 
N % N % n % 
Absence 2 20 0 0 0 0 0.000 
Mild 8 80 15 100 3 30 
Moderate 0 0 0 0 7 70 
* p value obtained from Chi Square Test 
p value less than 0.05 was considered statistically significan 
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Fig 1 
 
Reagents used 
 
Fig 2 
 
Antibodies Used 
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Figure 3. Lymphangiogenesis 
 
 
 
(Clockwise from top left) Tumor growth occurs, and as the tumor enlarges 
and secretes lymphangiogenic cytokines, new lymphatics grow toward the edge of 
the tumor. Intratumoral lymphangiogenesis may occur. Tumor cells invade the 
extracellular matrix and move toward the lymphatic capillaries. Malignant cells 
invade into the lymphatic lumen and move, singly or in clusters, with the lymphatic 
stream into the sentinel lymph node. Tumor cells enter the node through the 
subcapsular sinus; from there, they invade the cortex of the lymph node and 
proliferate and metastasize to other lymph nodes.) Courtesy : Zhuang et al, Int J of 
Oral Sci, 2010 
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Fig. 4. Lymphatic Markers 
Name Function Lymphatics 
Blood 
Vessel 
 Lymphatic Endothelial 
Vascular Endothelial 
Hyaluronan Receptor – 1 
(LYVE-1) 
Hyaluronan receptor on lymphatic 
endothelium 
+++ + 
Prox-1(Prospero Homeobox 
Protein -1) 
Homeobox gene +++ + 
Podoplanin 
38kDa member glycoprotein of 
podocytes 
+++ - 
Desmoplakin 
Inner plaque of desmosomes and 
associates with desmosomal 
cadherins 
++ - 
5‟-Nucleotidase Enzyme +++ - 
Vascular Endothelial Growth 
Factor Receptor -3 
(VEGFR – 3) 
Growth factor receptor +++ +++ 
VEGFR-2 Growth factor receptor + +++ 
Plasmalemma Vesicle Protein 
(PV-1/PAL-1) 
 _ +++ 
Factor VIII Von Willebrand clotting factor + +++ 
Laminin 
Basement membrane of 
endothelial cells – cell attachment 
and growth 
- +++ 
Platelet Endothelial Cell 
Adhesion Molecule – 1 
(PECAM-1) 
CD31, Vascular cell adhesion 
molecule 
++ +++ 
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Fig. 5 A 
 
D2-40 positive lymphatic vessels in a tissue section of a lymph node 
 
Fig. 5 B 
 
      Selective positivity of D2-40 for lymphatic vessels (yellow arrow) and 
negative for blood vessels (red arrow) 
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Fig. 6 
 
Sparse lymphatic vessels in a tissue section of normal buccal mucosa 
 
 
Fig 7 A 
 
D2-40 positive lymphatic vessels in a tissue section of non  
metastatic OSCC 
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Fig 7 B 
 
D2-40 positive lymphatic vessels in a tissue section of non metastatic OSCC 
 
Fig. 8 A 
 
D2-40 positivity in a tissue section of Metastatic OSCC 
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Fig. 8 B 
 
D2-40 positivity in a tissue section of Metastatic OSCC 
 
Fig. 9 A 
 
D2-40 positivity in basal layer of the epithelium adjacent to the tumor islands 
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Fig. 9 B 
 
D2-40 positivity in basal layer of the epithelium with sub epithelial 
inflammatory cell infiltrate 
 
Fig. 10 A 
 
D2-40 positivity in the periphery of tumor islands in well differentiated OSCC 
 
71 
 
Fig. 10 B 
 
D2-40 positivity in the periphery of tumor islands in well differentiated OSCC 
 
Fig. 11 A 
 
D2-40 positivity not restricted to basement membrane of tumor cells in the 
connective tissue of poorly differentiated OSCC 
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Fig. 11 B 
 
D2-40 positivity not restricted to the basement membrane of tumor cells in the 
connective tissue of poorly differentiated OSCC 
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                            Discussion 
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Nodal metastasis is one of the prime determinants of OSCC prognosis. 
Tumor cells may metastasize by expansion and invasion of pre-existing peritumoral 
lymphatics or by the induction and invasion of newly formed lymphatics
73
. 
Numerous studies have evaluated peritumoral lymphatics and established the 
presence of peritumoral lymphatic proliferation in metastatic lesions. The present 
study was done to study the involvement of tumoral lymphatics in OSCC. 
In our study, the mean age of the patients with non metastatic OSCC, 
metastatic OSCC and control groups was 57.46 ± 14.88 years, 62.5 ±12.93 years and 
27.6 ± 4.35 respectively. In a study done by Adhemer et al
74
, the mean age was 50 
years among the OSCC group. Mayumi et al
75
 studied a group of 110 OSCC patients 
of whom 48.2% were below 65 years of age and 51.8 were above 65 years of age. 
The younger age in the control group is due to the fact that the individuals who were 
asked for informed consent to have a biopsy of their normal buccal mucosa done 
electively, were patients who had come for removal of their impacted third molars 
and hence were predominantly in the 20 to 30 years age group.  
Among the OSCC patients (n=25) included in our study, 80% (n=20) were 
males and 20% (n=5) were females. This was similar to the study group of, 
Adhemer et al
74
, Mayumi et al
75 
and Ping Yuan et al
76
. The increased prevalence in 
males can be attributed to the habits of substance use, smoking and alcohol 
consumption in that population. Since archival blocks were used for the study, all 
the cases did not have records of habit history. So the influence of habits on the 
aggression and invasiveness of OSCC could not be evaluated. 
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A tissue section of a normal lymph node was taken as the positive control 
and the endothelial cells of lymphatic vessels showed strong positivity for D2-40 in 
our study. Out of 10 cases in the metastatic OSCC group, all the cases showed D2-
40 positive lymphatic vasculature. Among the 15 non metastatic OSCC cases, all the 
cases showed D2-40 positive lymphatic vessels. 80% of the cases in the control 
group showed D2-40 positive lymphatic vessels. Absence of staining in the two 
cases of the control group was due to inadequate tissue. The antibody revealed high 
specificity to lymphatic vessels and was negative for blood vessels because D2-40 is 
a monoclonal antibody against an oncofetal antigen which is a 40-kDa 
sialoglycoprotein that is highly expressed on the surface of lymphatic endothelial 
cells and not on blood vascular endothelial cells
6
. The precise staining of lymphatic 
vessels in the tissue sections from our study is consistent with that established in 
formerly published studies.  
We observed intense D2-40 staining in the neoplastic epithelial cells. Similar 
D2-40 staining of tumor cells in carcinomas has been reported in literature
5
. It has 
been described that D2-40 is specific for M2A region of podoplanin, a molecule 
found to be overexpressed in some tumor cells
5
. Even though the biologic functions 
of M2A region of podoplanin have not been completely studied, it has been 
observed that increased expression of the protein can encourage the formation of 
elongated cell extensions and augment adhesion, migration, and tube formation of 
vascular endothelial cells, signifying the role of podoplanin in cytoskeletal 
reorganization
8
. Wicki et al
80
 demonstrated, using mice model, that overexpression 
of podoplanin causes cellular changes followed by increased cellular migration. 
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They also reported a peripheric tumoral staining pattern as seen in our study. Based 
on these findings, they recommended that podoplanin might play a crucial part in a 
unique molecular pathway of combined cell migration independently from other 
pathways such as cadherin switch and epithelial-mesenchymal transition
80
. These 
findings indicate the probable potential of D2-40 in differentiation of 
histopathologic grades of OSCC, in addition to the lymphatic vessel positivity. 
On studying the pattern of this basal cell staining, we observed that the basal 
layer did not show D2-40 positivity in the epithelium of all the groups. The basal 
layer of epithelium that had inflammatory infiltrate juxta epithelially in Group 3 or 
that had tumor islands in the connective tissue in close proximity to the epithelium 
in Group 1 and Group 2, alone took the stain. D2-40 positivity was seen in the cells 
of the peripheral layer of the tumor islands in well differentiated OSCC and the 
central areas had not taken up the stain. In poorly differentiated OSCC, the D2-40 
positive cells were not restricted to the basement membrane cells. Similar pattern of 
distribution has been reported in a study by Scahcht et al
5
, the reason for which is 
not clear. 
Well differentiated OSCC consisted of 86.6% of the total number of OSCCs 
studied, and this was similar to the study by Adhemer et al
74
. 40% of the OSCC 
studied were positive for lymph node metastasis similar to the study by Mayumi et 
al
75
. 
The lymphatic vessel intensity of metastatic OSCC group was higher than 
that of the non metastatic OSCC group which was in turn higher than that of the 
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control group (p=0.000). This was similar to the results reported by Mayumi 
Miyahara et al
75
 and Palomba et al
77
.  
On comparison of the number of lymphatic vessels/mm
2
 of the tissue, 
between the metastatic OSCC group showed an increase in number compared to the 
non metastatic OSCC group, which in turn was higher than the control group 
(p=0.000). This is similar to the results of Zhao et al
78
 and Kyzas et al
73
.  
The non metastatic OSCC group showed higher number of vessels/mm
2
 
when compared to the control group (p=0.001), the metastatic OSCC group showed 
higher number of lymphatic vessels/mm
2
 when compared to the control group 
(p=0.000). On comparing the non metastatic and metastatic OSCC group, the latter 
showed increased vessel density (p=0.001). These results were consistent with those 
reported by Ping Yuan et al
76
 in which patients whose tumors expressed high levels 
of podoplanin had a statistically significantly higher rate of lymph node metastasis 
(p <.0001).  
On assessing the expression of D2-40 in different histopathologic grades of 
OSCC, moderately and poorly differentiated OSCC showed higher lymphatic vessel 
density when compared to well differentiated OSCC but this was not statistically 
significant (p=0.075). Inoue et al 
79
 reported that enhanced podoplanin expression 
was significantly associated with a poor pathologic grade of differentiation 
(p<0.020).  
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Studies on tumor progression have established that as the tumor advances, 
the cancer cells secrete lymphangiogenic cytokines which cause 
lymphangiogenesis
23
. Intratumoral lymphatics have several small ill defined lumina 
and are more proliferative when compared to peritumoral lymphatics
25
. This 
explains the increased number of lymphatic vessels seen in our study in the OSCC 
groups when compared to the control group. And as the lesion advances and more 
tumor cells proliferate, it causes a hypoxic environment, due to increased demand of 
oxygen by the tissues to meet the proliferation, which leads to production of growth 
factors that induce neoangiogenesis and lymphangiogenesis
25
. This accounts for the 
relatively higher number of lymphatic vessels seen in metastatic OSCC group than 
the non metastatic OSCC group in our study. These findings indicate that patients 
who have an elevated lymphatic vessel density may have a higher risk for lymph 
node metastasis and supports the hypothesis that lymphatic vessel density is 
accountable for the lymphatic spread in oral cancer
23
. 
Only two cases of poorly differentiated OSCC were studied, hence, the 
correlation between podoplanin expression and pathologic grade of differentiation 
could not be established with certainty. We did not have data regarding the patient’s 
response to treatment, and hence could not ascertain whether the lesions that showed 
an increased lymphatic vessel density responded poorly to treatment. 
This study, conducted on a larger study sample, prospectively, could 
establish if increased lymphatic vasculature had an effect on the disease prognosis in 
the Indian population. Also a larger sample size would provide more representative 
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tissue from all histopathologic grades of carcinoma, so that an association between 
lymphatic vasculature and histopathologic grade can be studied. 
Due to positive staining of the tumor cells by the antibody, it was important 
to meticulously distinguish between minute lymphatic vessels admixed between the 
diffusely distributed tumor cells, while counting the vaculature in cases of 
moderately differentiated and poorly differentiated OSCC. Also, the difference of 
staining pattern of the tumor cells between different histopathologic grades must be 
examined in a larger sample size, to establish if the difference in pattern seen in this 
study was consistent among the different grades, so that D2-40 staining pattern of 
tumor cells could also be employed to make a distinction between well differentiated 
OSCC and moderately/poorly differentiated OSCC. 
The impediments in distinguishing lymphatics from blood capillaries in 
formalin-fixed, paraffin-embedded tissues has been overcome to a certain extent by 
the advent of the new monoclonal antibody D2-40, which selectively recognizes 
lymphatic vessels. This antibody intensely labels lymphatic endothelial cells and 
tumor cells of OSCC, as accounted previously, highlighting the presence of 
lymphatic invasion in tumors. 
Our results indicate that D2-40 has the potential to be an effective marker to 
predict OSCC aggressiveness because lymphatic vessel density and D2-40 positivity 
in cancer, was associated with lymphatic vessel density. Thus, staining with D2-40 
may help in determining the prognosis of OSCC. Association of differences in D2-
40 staining pattern of tumor cells between different pathologic grades of OSCC may 
also be of diagnostic use and needs to be studied further. 
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      Summary and Conclusion   
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This immunohistochemical study comprised of a total of thirty five subjects 
in three groups: ten in metastatic OSCC (Group 1), fifteen in non metastatic OSCC 
(Group 2) and ten in control group (Group 3). D2-40 monoclonal antibody against 
lymphatic endothelial cells was used to study the lymphatic vessel density between 
the 3 groups. 
The conclusions of the study are: 
 D2-40 positivity is specific to lymphatic endothelial cells and absent in 
endothelial cells of blood vessels. 
 Lymphatic vessel density is higher in non metastatic OSCC group when 
compared to the control group (p=0.001). 
 Lymphatic vessel density is higher in the metastatic OSCC group when 
compared to the normal group (p=0.000). 
 Lymphatic vessel density is higher in the metastatic OSCC group when 
compared to non metastatic OSCC group (p=0.001) 
 Lymphatic vessel density is higher in metastatic OSCC group than non 
metastatic OSCC group which is in turn higher than the control group 
(p=0.000) 
 Lymphatic vessel density is higher, but not statistically significant in 
poorly differentiated and moderately differentiated OSCC when 
compared to well differentiated OSCC. 
 D2-40 stained the basal layer of the surface epithelium having  
sub epithelial inflammatory cell infiltrate and those adjacent to tumor 
islands. 
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 D2-40 immunoreactivity was diffuse in poorly and moderately 
differentiated OSCC. It was restricted to the basal cells in well 
differentiated OSCC. 
Our results indicate that D2-40 has the potential to be a surrogate marker of 
OSCC aggressiveness because lymphatic vessel density and D2-40 positive reaction 
in cancer cells were associated with lymphatic vessel density. Thus, staining with 
D2-40 may be important in determining the prognosis of OSCC.  
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Annexure 2: Lymphatic vessels per mm
2 
in the cases 
Case no Lymphatic Vessels/mm2 No. of grids counted 
Group 1 
S-102 8.833 6 
S-268 4 4 
S-1332 2.794 34 
S-650 6.444 18 
S-213 0.814 27 
S-153 6.217 23 
S-1065 5.986 50 
S-1035 5.56 24 
4225/11-C 8.9 22 
S-703 7.97 34 
Group 2 
4071/11 3.6 12 
4232/11 1.44 14 
4265/11 0.733 29 
4231/11 0.733 19 
4163/11-B 0.666 52 
3966/11 2.176 13 
4270/11 3.143 10 
4229/11 3.2 20 
S-653 2.181 32 
S-1021 2.666 35 
S-097 1.625 22 
S-256 1.571 17 
S-4137 3.6 28 
S-315 2.428 43 
4227/11 2.444 12 
Group 3 
4054/11 0 11 
4055/11 0 6 
4056/11 0.166 6 
4057/11 0.285 7 
4058/11 2.285 14 
4059/11 0.2 5 
4468/11 0.37 11 
4469/11 0.222 3 
4445/11 1.785 6 
4463/11 0.2 6 
 
